Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia.
Francesco SaltonPaola ConfalonieriG Umberto MeduriPierachille SantusSergio HarariRaffaele ScalaSimone LaniniValentina VertuiTiberio OggionniAntonella CaminatiVincenzo PatrunoMario TamburriniAlessandro ScartabellatiMara ParatiMassimiliano VillaniDejan RadovanovicSara TomassettiClaudia RavagliaVenerino PolettiAndrea VianelloAnna Talia GaccioneLuca GuidelliRita RaccanelliPaolo LucernoniDonato LacedoniaMaria Pia Foschino BarbaroStefano CentanniMichele MondoniMatteo DavìAlberto FantinXueyuan CaoLucio TorelliAntonella ZucchettoMarcella MonticoAnnalisa CasarinMicaela RomagnoliStefano GaspariniMartina BonifaziPierlanfranco D'AgaroAlessandro MarcelloDanilo LicastroBarbara RuaroMaria Concetta VolpeReba UmbergerMarco ConfalonieriPublished in: Open forum infectious diseases (2020)
In patients with severe COVID-19 pneumonia, early administration of prolonged MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence. Treatment was safe and did not impact viral clearance. A large randomized controlled trial (RECOVERY trial) has been performed that validates these findings. Clinical trial registration. ClinicalTrials.gov NCT04323592.